Kemwell makes Rs 250-cr foray into biopharma

摘要

PUREPLAY contract pharmaceutical manufacturer Kemwell P Ltd has forayed into biopharmaceuticals by setting up a Rs 250-crore division called Kemwell Biologies. The family-owned company has tied up with German major Boehringer Ingelheirri for the technology platform that will potentially widen its clientele to small and big bio-research labs and companies globally. More importantly, it would help Kemwell's entry to the regulated markets of the US and Europe, according to Kemwell's Chariman & Managing Director, Mr Subhash Bagaria. The investment was from company resources and part debt.